IB COMMUNICATIONS PRESS RELEASES

Kansas City, USA, April 17, 2024 – Likarda, a leading biotech company specializing in the development of enabling technologies for the delivery of both cell therapies and large molecule biologics, today announces the appointment of Shelly Adams as Chief Commercial Officer. Shelly joins Likarda from Erbi Biosystems, part of Millipore Sigma, where she served as Vice President of Sales......

Mont-Saint-Guibert, Belgium, April 12, 2024 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, as part of the global restructuring plan announced on 11 April 2024, provides information on (i) the Company's current debt position and the potential impact of the plan on this position .....

Mont-Saint-Guibert, Belgium, April 11, 2024 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy announces that it has finalised a draft plan with the request referred to in Article XX 83/26 ELC with the Enterprise Court of Nivelles. Creditors will be notified to register their claims in RegSol. They will be able to consult this plan in order to then vote on the proposals made.

Ormond Beach, Florida and Germantown, Maryland, April 10, 2024 - Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global leader in decentralizing cell and gene therapies (CGTs), today announced an asset purchase and strategic partnership aimed at advancing Orgenesis’ therapeutic programs

Giessen, Hesse, Germany, April 9 2024 – Green Elephant Biotech GmbH, the world's first company to develop, manufacture and sell consumables for laboratories made from plant-based plastics, is expanding its product line of plant-based 96-well plates with two new additions for fluorescence- and luminescence-based assays. The new black and white microtiter plates....

Miami, Florida, April 3, 2024 – OrganaBio, the cell and gene therapy industry’s hub for tissue sourcing, cell isolation, cryopreservation, contract manufacturing services, and clinical sample processing, today announced the launch of HematoPAC™-HSC-CB-GMP, on-demand current good manufacturing practice (cGMP)-compliant CD34+ hematopoietic stem cells....

Mont-Saint-Guibert, Belgium, March 29, 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published....

Mont-Saint-Guibert, Belgium, 20 March 2024, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, presented the latest data on arsenic trioxide (ATO) for systemic sclerosis (SSc) at the 8th Systemic Sclerosis World Congress 2024. The data, obtained with the laboratory of Yannick Allanore, MD, Ph.D. from the Hospital Cochin, builds additional evidence....

Lakewood, Colorado, and Kyoto, Japan, March 19, 2024 – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, and CiRA Foundation, a public interest organization for the transfer of induced pluripotent stem (iPS) cells to industry, today announced a partnership designed to propel the broad use of iPS cells for a range of new therapies. By leveraging CiRA Foundation’s leading iPS cell knowledge and Terumo BCT’s enabling technologies....

Mont-Saint-Guibert, Belgium, 12 March 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces the publication of an open-access article describing an optimized schedule for administration of oral arsenic trioxide (OATO) treatment for chronic graft-versus-host disease (cGvHD), based on an earlier post-hoc analysis of Phase 2 data. The schedule will play an important role in the protocol for BioSenic’s forthcoming pivotal Phase 3 clinical trial.

Lakewood, Colorado and Newark, N.J., February 29, 2024 – Today, Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company , and BioCentriq, a global cell therapy contract development and manufacturing organization (CDMO), will share the first data resulting from its chimeric antigen receptor (CAR)-T cell therapy manufacturing collaboration today at the 7th CAR TCR Summit Europe. The data will demonstrate, for the first time, the ability to rapidly produce CAR-T cells using protocols developed by Terumo BCT ....

Mont-Saint-Guibert, Belgium, 29 February 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information ....

Cardiff, UK, February 28, 2024 – TrakCel, the leading and proven provider of cellular orchestration systems to the global cell and gene therapy (CGT) industry, announces the coming expansion of its OCELLOS partner ecosystem, which will bring the total number of integrated partners to 20 by the end of 2024. The growth will mean developers using OCELLOS for cellular orchestration....

Mulhouse, France, February 27 2024 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, announces a collaboration with stem cell leaders at Shonan Kamakura General Hospital (SKGH), Japan, to manufacture autologous endothelial progenitor cells (EPCs) in forthcoming clinical trials. SKGH researchers led by world-renowned stem cell expert Takayuki Asahara, M.D., Ph.D., will deploy CellProthera’s clinically validated StemXpand(R) automated ....

Lakewood, Colorado, 19 February, 2024 - Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company , announced the publication of a peer-reviewed study [1] containing new consensus recommendations from an international panel of multidisciplinary experts for sickle cell disease (SCD) management during pregnancy. The Terumo BCT-sponsored study spells out....

Wednesday, 14th February 2024 - Children, young people, and adults across England suffering from sickle cell disease will soon benefit from better care closer to where they live, following the announcement of a £1.5m investment in 25 red blood cell exchange devices. Funding for the Spectra Optia(R) Apheresis System devices has been distributed to 22 NHS trusts*, with the devices set to be installed in hospitals for the treatment of patients by the end of March 2024.

Mont-Saint-Guibert, Belgium, 2 February 2024 – BioSenic (Euronext Brussels and Paris: BIOS),

Mont-Saint-Guibert, Belgium, January 31, 2024 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it will attend and support the upcoming GvHGvL Meeting on 13-15 March, 2024 at University Hospital Regensburg, a biannual conference to lead scientific exchange around graft-versus-host disease (GvHD).

Berlin, Germany, January 31, 2024 – Green Elephant Biotech GmbH, the world's first company to develop, manufacture and sell consumables for laboratories made from plant-based plastics, today announces the commercial launch of the first-of-its-kind plant-based Green Elephant 96-Well Plate. For the first time, laboratory staff can conduct research, diagnoses and analysis more sustainably without compromising quality, all while meeting safety and purity standards. The plate is designed to replace single-use, fossil fuel-based plastic plates.

Mont-Saint-Guibert, Belgium, 30 January 2024 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell repair therapy, today announces the granting of a key patent by the Canadian Intellectual Property Office to expand protection of the arsenic trioxide (ATO) platform. The patent, titled “Use of metal ions to potentiate the therapeutic effects of arsenic,” covers the use of ATO platform....

Mont-Saint-Guibert, Belgium, January 25 2024 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, will for the first time share post hoc data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024. The post hoc analysis of a Phase 3 study found that a single injection ....

Mont-Saint-Guibert, Belgium, January 23, 2024 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company focused on serious autoimmune and inflammatory diseases and cell therapy, today announces the filing of a U.S. patent for JTA-004, a viscosupplement in late-stage clinical development, following new evidence of its efficacy in a recently defined subtype of osteoarthritis (OA).

Besançon, France, January 16, 2024 – CellQuest, a developer and manufacturer of automated chimeric antigen receptor (CAR)-T cell production platforms and solutions, today announces the launch of its Early Access Program (EAP) to introduce the CosyNest manufacturing platform to cell therapy developers. CosyNest, a closed manufacturing system, has been designed to dramatically increase the production of CAR-T cells per person, and per unit area.

Cardiff, UK, January 16, 2024 – TrakCel, the leading and proven provider of cellular orchestration systems to the global cell and gene therapy (CGT) industry, today launched TrakCel Consultancy Services to efficiently share its extensive process development experience with the broader community of CGT developers. The new consultancy services...

Miami, Florida, January 16, 2024 – OrganaBio, the hub for tissue sourcing, cell isolation, clinical sample processing, cryopreservation, and contract manufacturing services to support cell therapy and immunotherapy development globally, has been named a Translator of the Year finalist at the upcoming Advanced Therapies Awards for its work to support a chimeric antigen receptor natural killer T-cell (CAR-NKT) therapy as it progresses into clinical trials.........

Mont-Saint-Guibert, Belgium, January 15, 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announce the signature of a binding term sheet with Phebra PTY Ltd. related to the adaptation of the License Agreement and the MDA signed in May 2021.

Mont-Saint-Guibert, Belgium, January 10, 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announces the promotion of Dr Carole Nicco to Chief Operating Officer (COO) in addition to her position as Chief Scientific Officer (CSO).

Mont-Saint-Guibert, Belgium, January 8, 2024 – BIOSENIC (Euronext Brussels and Paris: BIOS), the company addressing unmet medical needs in auto-immune diseases and orthopedics, today announces that it has signed a new subscription agreement for a maximum EUR 1.2 million convertible bonds ("CBs") facility, arranged by ABO Securities through its affiliated entity Global Tech Opportunities 15 ("GTO 15").